- Home
- GNPX vs HSCS Comparison
GNPX vs HSCS Comparison
Compare GNPX & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- HSCS
- Stock Information
- Founded
- GNPX 2009
- HSCS 2007
- Country
- GNPX United States
- HSCS United States
- Employees
- GNPX N/A
- HSCS N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- HSCS Medical Specialities
- Sector
- GNPX Health Care
- HSCS Health Care
- Exchange
- GNPX Nasdaq
- HSCS Nasdaq
- Market Cap
- GNPX 9.4M
- HSCS 9.9M
- IPO Year
- GNPX 2018
- HSCS 2022
- Fundamental
- Price
- GNPX $0.24
- HSCS N/A
- Analyst Decision
- GNPX
- HSCS Strong Buy
- Analyst Count
- GNPX 0
- HSCS 2
- Target Price
- GNPX N/A
- HSCS $10.50
- AVG Volume (30 Days)
- GNPX 3.8M
- HSCS 94.3K
- Earning Date
- GNPX 11-12-2025
- HSCS 09-11-2025
- Dividend Yield
- GNPX N/A
- HSCS N/A
- EPS Growth
- GNPX N/A
- HSCS N/A
- EPS
- GNPX N/A
- HSCS N/A
- Revenue
- GNPX N/A
- HSCS $6,250.00
- Revenue This Year
- GNPX N/A
- HSCS $13,968.97
- Revenue Next Year
- GNPX N/A
- HSCS $166.67
- P/E Ratio
- GNPX N/A
- HSCS N/A
- Revenue Growth
- GNPX N/A
- HSCS N/A
- 52 Week Low
- GNPX $0.14
- HSCS $2.52
- 52 Week High
- GNPX $3.97
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- GNPX 48.99
- HSCS 53.94
- Support Level
- GNPX $0.19
- HSCS $3.57
- Resistance Level
- GNPX $0.22
- HSCS $3.80
- Average True Range (ATR)
- GNPX 0.02
- HSCS 0.17
- MACD
- GNPX -0.00
- HSCS 0.02
- Stochastic Oscillator
- GNPX 49.82
- HSCS 62.50
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.